The Hedge Fund Senzar Asset Management Llc Upped its Position in Exact Sciences Corp (Put) (NASDAQ:EXAS) by $21.45 Million

May 17, 2018 - By Laura Small

Exact Sciences Corporation (NASDAQ:EXAS) Corporate LogoBig Money Sentiment decreased to 0.88 in Q4 2017. It has change of 0.13, from 2017Q3’s 1.01. The ratio worsened due to EXAS positioning: 25 sold and 105 reduced. 44 funds took positions and 70 increased positions. Investors holded 93.65 million in 2017Q3 but now own 92.48 million shares or 1.24% less. Blackrock Inc owns 7.66M shs for 0.02% of their capital. Schwab Charles Investment Mngmt holds 0.03% or 765,522 shs in its capital. Moneta Group Investment Advisors Ltd holds 0.06% or 7,334 shs in its capital. Northwestern Mutual Wealth Mngmt Co owns 0% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 6,303 shs. Jane Street Group Ltd owns 19,779 shs. Huntington Financial Bank holds 0% or 1,023 shs. Palo Alto Limited Liability Corporation reported 310,876 shs. Natl Bank Of Montreal Can reported 31,254 shs or 0% of all its holdings. Comerica Bancorp invested in 4,188 shs or 0% of the stock. Antipodean Ltd accumulated 24.63% or 577,346 shs. Putnam Lc accumulated 38,121 shs. Winch Advisory Svcs Ltd Liability holds 0% of its capital in Exact Sciences Corporation (NASDAQ:EXAS) for 19 shs. 1.27M were reported by Wasatch Advsr. Rhumbline Advisers holds 121,852 shs or 0.01% of its capital. Winslow Evans Crocker Incorporated invested in 0% or 22 shs.

EXAS registered $25.11 million net activity with 0 buys and 21 insider sales since January 2, 2018. $141,341 worth of Exact Sciences Corporation (NASDAQ:EXAS) shs were sold by COWARD D SCOTT. On Monday, February 26 $243,068 worth of stock was sold by ARORA MANEESH. On Monday, February 26 LIDGARD GRAHAM PETER sold $1.50 million worth of Exact Sciences Corporation (NASDAQ:EXAS). The insider Elliott Jeffrey Thomas sold $126,252. Shares for $126,925 were sold by Doyle James Edward. Zanotti Katherine S sold $325,440 worth of Exact Sciences Corporation (NASDAQ:EXAS) on Thursday, April 12.

The stake In Exact Sciences Corp (Put) (NASDAQ:EXAS) owned by Senzar Asset Management Llc was increased. According to 2018Q1 SEC regulatory report the increase is 9679.82%. 536,359 shares were bought by Senzar Asset Management Llc as Exact Sciences Corp (Put) (NASDAQ:EXAS) stock declined 19.82% with the market. In 2018Q1, the 541,900 shares in Exact Sciences Corp (Put) (NASDAQ:EXAS) held by Senzar Asset Management Llc were priced $21.86M, up from 5,541 last quarter. $6.21B is the Exact Sciences Corp (Put)’s market cap. The stock increased 0.37% or $0.19 during the last trading session, reaching $50.96.Exact Sciences Corporation has volume of 1.04M shares. Since May 17, 2017 EXAS has risen 81.43% and is uptrending. EXAS outperformed the S&P500 by 69.88%.

Senzar Asset Management Llc operates about $442.00 million and $316.94 million US longs. According to a filing the fund reduced its stake in Sanofi (NYSE:SNY) by 488,340 shares to 511,446 shares, valued at $20.50 million in 2018Q1. It decreased Tg Therapeutics Inc (NASDAQ:TGTX) position by 879,260 shares to 475,918 shares, and cut its Regeneron Pharmaceuticals (NASDAQ:REGN) stake.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

A total of 11 analysts rate Exact Sciences (NASDAQ:EXAS) as follows: 8 “Buy”, 3 “Hold” and 0 “Sell”. Тherefore 73% are bullish. (NASDAQ:EXAS) has 16 ratings reports on 17 May 2018 according to StockzIntelligence. On Monday, March 19 Canaccord Genuity maintained Exact Sciences Corporation (NASDAQ:EXAS) with “Buy” rating. On Tuesday, April 3 the stock has “Buy” rating by BTIG Research. On Wednesday, January 17 the rating was maintained by Benchmark with “Buy”. On Tuesday, February 27 the firm has “Outperform” rating given by Robert W. Baird. On Wednesday, March 28 the firm has “Buy” rating by Leerink Swann given. On Tuesday, March 27 the company was maintained by Jefferies. In Wednesday, December 20 report Cowen & Co maintained it with “Buy” rating and $65.0 target. On Friday, February 23 Stephens maintained the shares of EXAS in report with “Hold” rating. On Friday, February 23 the rating was maintained by Canaccord Genuity with “Buy”. On Friday, April 27 the stock has “Buy” rating by Canaccord Genuity.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The firm is worth $6.21 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Currently it has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: